Age Related Vision Dysfunction Market
Market Insights on Age Related Vision Dysfunction covering sales outlook, demand forecast & up-to-date key trends
Age Related Vision Dysfunction Market by Dysfunction Type, Drug & Region | Forecast 2023 to 2033
Age Related Vision Dysfunction Market Snapshot (2022 to 2033)
The global age-related vision dysfunction market garnered a market value of US$ 90 Billion in 2023 and is expected to accumulate a market value of US$ 130 Billion by registering a CAGR of 3.7% in the forecast period 2022 to 2033.
The general public's desire to correct and enhance their eyesight as a consequence of increased eye disorders, an aging population, and a variety of other causes is likely to boost the market for age-related vision dysfunction products throughout the forecast period. The adoption of electronic gadgets has been rapidly increasing. People frequently utilize such gadgets for extended periods of time. As a result, more and more individuals are suffering from age-related vision dysfunction, including Asthenopia, and people have begun to use vision care products, particularly vision care eye drops and vision care capsules.
Moreover, poor nutrition and a lack of attention to health are two other issues that are projected to raise demand for the age-related vision dysfunction market. As a result of poor eating, an increasing number of people are experiencing partial or complete eyesight loss. The adoption of electronic gadgets has increased rapidly. Furthermore, vision care products are now more widely available than ever before. Because of such a robust logistics and supply chain network, vision care items such as eyeglasses, cooling glasses, and so on may be transferred quickly within a region or from one nation to another. This is also expected to boost the age-related vision dysfunction market throughout the projected period.
|
Data Points |
Key Statistics |
|
Expected Market Value (2023) |
US$ 90 Billion |
|
Anticipated Forecast Value (2033) |
US$ 130 Billion |
|
Projected Growth Rate (2023 to 2033) |
3.7% CAGR |
Let us know your requirement to get
100% FREE customization
Age Related Vision Dysfunction Demand Analysis (2017 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for age-related vision dysfunction is projected to increase at a CAGR of 3.7% during the forecast period between 2022 and 2033, reaching a total of US$ 130 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 2%.
The prevalence of rising eye disorders among individuals from all walks of life is predicted to fuel demand for age-related vision dysfunction, notwithstanding a major increase. The number of patients attending eye care hospitals has increased due to a rise in incidences of cataracts and glaucoma. According to WHO figures, more than 4.5 million individuals are blind as a result of glaucoma. This is concerning, and it has pushed glaucoma patients to adopt preventive measures.
Which are Some Prominent Drivers of Age Related Vision Dysfunction Market?
An Increase in the Proportion of Geriatrics to Encourage Market Expansion
As people age, their eye lenses get stiffer, making it difficult to focus on objects in close proximity. This disorder is known as presbyopia, and it is frequent in persons over the age of 70.
This is usually corrected by using bifocal or progressive lenses. During the projection period, this is likely to improve growth prospects of age-related vision dysfunction.
Advancements in Ophthalmic Diagnostic and Treatment Technologies to boost Adoption
The technical developments that are occurring in this sector are the primary drivers of the age-related vision dysfunction industry. The use of nanotechnology in vision care is predicted to revolutionize the market.
Nanotechnology is now being used to detect eye pressure, cure retinal disorders, and help patients recover from glaucoma faster. Furthermore, robots are used in conjunction with human intelligence to precisely place surgical equipment during eye surgery. Artificial retinas with electrodes are used to replace injured retinas. This might increase future demand for age-related vision dysfunction treatment.
Increasing Awareness-raising Campaigns concerned with Eye Dysfunction
Whether it is the government or large corporations, they are all taking measures to raise awareness about age-related vision dysfunction and its treatment. The World Health Organization (WHO) and the International Agency for the Prevention of Blindness (IAPB) partnered with the Indian government to create VISION 2020. They also put on World Sight Day and other activities.
The goal was to raise awareness about various eye disorders and the procedures to take to keep healthy eyes. This might boost the age-related vision dysfunction market throughout the predicted period. Artificial retinas with electrodes are used to replace injured retinas. This might increase future demand for age-related vision dysfunction treatments.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich are the Trough Areas faced by the Age Related Vision Dysfunction Market?
High Price of Medication to Hamper Market Growth
The high pricing of medications is going to put pressure on corporations and drug makers, particularly on therapies with a high price (i.e. gene therapies) that provide no additional major advantages.
Region-Wise Insights
How will Age-Related Vision Dysfunction Market Demand progress in the Asia Pacific?
Rapid Technological Development for Widening Profit Margins
During the projected period, the Chinese age-related vision dysfunction market is predicted to develop at a healthy CAGR of 3.6%. Some of the reasons driving the Chinese age-related vision dysfunction market are the raising geriatric population, rapid technological development, and a growing inclination for superior eye care goods.
According to a Lancet investigation, there were more than 45 million individuals in China with moderate visual impairment, 4.6 million with severe vision impairment, and about 8.7 million with blindness. Furthermore, according to studies, China is one of the world's largest markets for age-related vision dysfunction treatments. Because of technical improvements, China's top businesses are offering novel vision care goods at cheap prices.
On the other hand, according to FMI research, the India age-related vision dysfunction market is estimated to develop at a CAGR of 3% over the forecast period. People have begun to adopt sedentary lifestyles as cities have grown in size. As a result, individuals begin to acquire numerous health concerns, the most evident of which is eye damage in many cases.
Furthermore, the use of technological gadgets is increasing. This opens up a big possibility for the vision care sector in the future. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.
How attractive are Growth Prospects for Age-Related Vision Dysfunction in North America?
Growing Senior Population to Accelerate Market Growth
According to FMI research, the North American age-related vision dysfunction market is predicted to develop at a CAGR of 3.6% during the forecast period. The market is likely to be driven by a growing senior population, favorable government policies, and an increase in the incidence of eye illnesses among individuals of all ages.
According to the Centers for Disease Control and Prevention, almost 12 million Americans over the age of 40 have vision impairment. This has been connected to an increase in diabetes incidence in the region. The government and several corporate entities are launching awareness campaigns to keep the issue under control.
Furthermore, the leading businesses are utilizing cutting-edge technology to provide the greatest products possible. Aside from that, the rapid expansion of the E-Commerce industry is predicted to fuel the market in the United States. The United States is predicted to be the top country in North America, with a market share of 33.8% in the area.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Which Dysfunction Type is the Most Prevalent in the Age-Related Vision Dysfunction Market?
The Glaucoma Segment Trends to enhance Sales Prospects
The increasing incidence of glaucoma, rising attempts to raise awareness about glaucoma, and technical breakthroughs in the area of ophthalmology are the primary drivers driving the growth of the glaucoma treatment sector.
Glaucoma is the world's second-largest cause of blindness. This is usually caused by increased intraocular tension. The basic purpose of treatment is to reduce intraocular tension. This is accomplished by either decreasing aqueous fluid secretion or boosting its outflow. Although glaucoma medications alleviate symptoms, there is no cure for this ailment.
Start-Ups for Age Related Vision Dysfunction Market
Key start-up players in the age-related vision dysfunction are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key age-related vision dysfunction start-ups are as follows:
- Nanodropper, Inc. was established in 2018. It has created an eye drop bottle converter that reduces the capacity of large eyedrops by more than 60%. This is done with the goal of reducing waste and costs.
- Visus Therapeutics is a company that was created in 2019. Their primary goal has always been to provide fixed formulation eye drops for presbyopia sufferers.
Market Competition
The main market participants are taking all feasible measures to execute the proper activities in order to lessen the rising number of age-related vision dysfunction sufferers globally. They are getting into strategic relationships with start-ups to solve some of the issues that patients confront when undergoing treatment for this purpose. The leading stakeholders are on a quest to create minimally invasive surgical treatments for this purpose. Key players in the age-related vision dysfunction market are:
- Aerie Pharmaceuticals
- Santen Pharmaceutical
- Sun Pharma Advanced Research Company Limited
- Bausch + Lomb
- D Western Therapeutics Institute
- Novartis
- AbbVie
- Eyenovia
- Orasis Pharmaceuticals
- IVERIC Bio
Recent Developments:
- In May 2020, AbbVie Inc. finalized the strategic acquisition of Allergan plc. As a result of this purchase, AbbVie Inc. has positioned itself as a market leader in the age-related vision dysfunction business.
- Santen Pharmaceutical Co. Ltd. launched DIQUAS® Ophthalmic Solution 3% (diquafosol sodium) in Japan in November 2022. The formulation contains a P2Y2 receptor agonist which stimulates tear production and improves eye tissue tear abnormalities.
- Bausch + Lomb Corporation announced in December 2022 that it has received FDA clearance 510(k) for its Biotrue Hydration Boost Contact Lens Rehydrating Drops. These drops are preservative-free, multi-dose, and suitable for soft and rigid gas-permeable contact lenses
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 90 Billion |
|
Market Value in 2033 |
US$ 130 Billion |
|
Growth Rate |
CAGR of 3.7% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Age Related Vision Dysfunction Market Industry Survey
Age Related Vision Dysfunction Market by Dysfunction Type:
- Cataract
- AMD
- Glaucoma
- Presbyopia
Age-Related Vision Dysfunction Market by Drug:
- Rocklatan
- Eybelis Ophthalmic Solution
- Xelpros
- Rhopressa
- Vyzulta
- Glanatec
- Simbrinza
- Tapcom/DE-111
- Azarga/Azorga
- Combigan
- Lucentis
- Eylea
- Beovu
Age-Related Vision Dysfunction Market by Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)
Frequently Asked Questions
What is the anticipated growth of the age related vision dysfunction market until 2033?
FMI projects the global age-related vision dysfunction market to expand at a 3.7% value CAGR by 2033
What is the estimated market value of Age Related Vision Dysfunction market expected in 2023?
The global Age Related Vision Dysfunction market is estimated at a market value of US$ 90 Billion
What is the estimated market value of Age Related Vision Dysfunction market expected in 2033?
The global Age Related Vision Dysfunction market is expected to garner a market value of US$ 130 Billion
Which region is forecast to be the most lucrative for Age Related Vision Dysfunction market growth?
As per Future Market Insights, Asia Pacific is expected to grow at a CAGR of 3.5% in the assessment period 2023 to 2033.
Which are some prominent automotive axle manufacturers?
Aerie Pharmaceuticals, Santen Pharmaceutical, Sun Pharma Advanced Research Company Limited, Bausch + Lomb, D Western Therapeutics Institute, Novartis, AbbVie, Eyenovia, Orasis Pharmaceuticals and IVERIC Bio are some prominent Age Related Vision Dysfunction manufacturers
What is the expected market share of North America in the Age Related Vision Dysfunction market?
As per Future Market Insights, North America is expected to grow at a CAGR of 3.6% in the assessment period 2023 to 2033.
What is the expected market share of Europe for Age Related Vision Dysfunction?
As per Future Market Insights, Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023 to 2033.
Which dysfunction type is expected to hold the largest market share for Age Related Vision Dysfunction in the forecast period 2023 to 2033?
The glaucoma segment is expected to hold the largest market share for Age Related Vision Dysfunction in the forecast period 2023-2033
Table of Content
1. Executive Summary | Age-Related Vision Dysfunction Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dysfunction Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Dysfunction Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dysfunction Type, 2023 to 2033 5.3.1. Cataract 5.3.2. AMD 5.3.3. Glaucoma 5.3.4. Presbyopia 5.4. Y-o-Y Growth Trend Analysis By Dysfunction Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Dysfunction Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033 6.3.1. Rocklatan 6.3.2. Eybelis Ophthalmic Solution 6.3.3. Xelpros 6.3.4. Rhopressa 6.3.5. Vyzulta 6.3.6. Glanatec 6.3.7. Simbrinza 6.3.8. Tapcom/DE-111 6.3.9. Azarga/Azorga 6.3.10. Combigan 6.3.11. Lucentis 6.3.12. Eylea 6.3.13. Beovu 6.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East & Africa (MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. The US 8.2.1.2. Canada 8.2.2. By Dysfunction Type 8.2.3. By Drug 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Dysfunction Type 8.3.3. By Drug 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Dysfunction Type 9.2.3. By Drug 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Dysfunction Type 9.3.3. By Drug 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. The UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Dysfunction Type 10.2.3. By Drug 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Dysfunction Type 10.3.3. By Drug 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Singapore 11.2.1.5. Thailand 11.2.1.6. Indonesia 11.2.1.7. Australia 11.2.1.8. New Zealand 11.2.1.9. Rest of Asia Pacific 11.2.2. By Dysfunction Type 11.2.3. By Drug 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Dysfunction Type 11.3.3. By Drug 11.4. Key Takeaways 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of MEA 12.2.2. By Dysfunction Type 12.2.3. By Drug 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Dysfunction Type 12.3.3. By Drug 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. The US 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2022 13.1.2.1. By Dysfunction Type 13.1.2.2. By Drug 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2022 13.2.2.1. By Dysfunction Type 13.2.2.2. By Drug 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2022 13.3.2.1. By Dysfunction Type 13.3.2.2. By Drug 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2022 13.4.2.1. By Dysfunction Type 13.4.2.2. By Drug 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2022 13.5.2.1. By Dysfunction Type 13.5.2.2. By Drug 13.6. The UK 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2022 13.6.2.1. By Dysfunction Type 13.6.2.2. By Drug 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2022 13.7.2.1. By Dysfunction Type 13.7.2.2. By Drug 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2022 13.8.2.1. By Dysfunction Type 13.8.2.2. By Drug 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2022 13.9.2.1. By Dysfunction Type 13.9.2.2. By Drug 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2022 13.10.2.1. By Dysfunction Type 13.10.2.2. By Drug 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2022 13.11.2.1. By Dysfunction Type 13.11.2.2. By Drug 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2022 13.12.2.1. By Dysfunction Type 13.12.2.2. By Drug 13.13. Singapore 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2022 13.13.2.1. By Dysfunction Type 13.13.2.2. By Drug 13.14. Thailand 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2022 13.14.2.1. By Dysfunction Type 13.14.2.2. By Drug 13.15. Indonesia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2022 13.15.2.1. By Dysfunction Type 13.15.2.2. By Drug 13.16. Australia 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2022 13.16.2.1. By Dysfunction Type 13.16.2.2. By Drug 13.17. New Zealand 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2022 13.17.2.1. By Dysfunction Type 13.17.2.2. By Drug 13.18. GCC Countries 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2022 13.18.2.1. By Dysfunction Type 13.18.2.2. By Drug 13.19. South Africa 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2022 13.19.2.1. By Dysfunction Type 13.19.2.2. By Drug 13.20. Israel 13.20.1. Pricing Analysis 13.20.2. Market Share Analysis, 2022 13.20.2.1. By Dysfunction Type 13.20.2.2. By Drug 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Dysfunction Type 14.3.3. By Drug 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Aerie Pharmaceuticals 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Santen Pharmaceutical 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Sun Pharma Advanced Research Company Limited 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Bausch + Lomb 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. D Western Therapeutics Institute 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Novartis 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. AbbVie 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. Eyenovia 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. Orasis Pharmaceuticals 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. IVERIC Bio 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Dysfunction Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Drug, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Dysfunction Type, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Drug, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Dysfunction Type, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Drug, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Dysfunction Type, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by Drug, 2018 to 2033 Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Asia Pacific Market Value (US$ Million) Forecast by Dysfunction Type, 2018 to 2033 Table 15: Asia Pacific Market Value (US$ Million) Forecast by Drug, 2018 to 2033 Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: MEA Market Value (US$ Million) Forecast by Dysfunction Type, 2018 to 2033 Table 18: MEA Market Value (US$ Million) Forecast by Drug, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Dysfunction Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Drug, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Dysfunction Type, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Dysfunction Type, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Dysfunction Type, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by Drug, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033 Figure 13: Global Market Attractiveness by Dysfunction Type, 2023 to 2033 Figure 14: Global Market Attractiveness by Drug, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Dysfunction Type, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by Drug, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Dysfunction Type, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Dysfunction Type, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Dysfunction Type, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Drug, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033 Figure 28: North America Market Attractiveness by Dysfunction Type, 2023 to 2033 Figure 29: North America Market Attractiveness by Drug, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Dysfunction Type, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by Drug, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Dysfunction Type, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Dysfunction Type, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Dysfunction Type, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by Drug, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Dysfunction Type, 2023 to 2033 Figure 44: Latin America Market Attractiveness by Drug, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Dysfunction Type, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by Drug, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Dysfunction Type, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Dysfunction Type, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Dysfunction Type, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by Drug, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033 Figure 58: Europe Market Attractiveness by Dysfunction Type, 2023 to 2033 Figure 59: Europe Market Attractiveness by Drug, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: Asia Pacific Market Value (US$ Million) by Dysfunction Type, 2023 to 2033 Figure 62: Asia Pacific Market Value (US$ Million) by Drug, 2023 to 2033 Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Dysfunction Type, 2018 to 2033 Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Dysfunction Type, 2023 to 2033 Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Dysfunction Type, 2023 to 2033 Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Drug, 2018 to 2033 Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033 Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033 Figure 73: Asia Pacific Market Attractiveness by Dysfunction Type, 2023 to 2033 Figure 74: Asia Pacific Market Attractiveness by Drug, 2023 to 2033 Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 76: MEA Market Value (US$ Million) by Dysfunction Type, 2023 to 2033 Figure 77: MEA Market Value (US$ Million) by Drug, 2023 to 2033 Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: MEA Market Value (US$ Million) Analysis by Dysfunction Type, 2018 to 2033 Figure 83: MEA Market Value Share (%) and BPS Analysis by Dysfunction Type, 2023 to 2033 Figure 84: MEA Market Y-o-Y Growth (%) Projections by Dysfunction Type, 2023 to 2033 Figure 85: MEA Market Value (US$ Million) Analysis by Drug, 2018 to 2033 Figure 86: MEA Market Value Share (%) and BPS Analysis by Drug, 2023 to 2033 Figure 87: MEA Market Y-o-Y Growth (%) Projections by Drug, 2023 to 2033 Figure 88: MEA Market Attractiveness by Dysfunction Type, 2023 to 2033 Figure 89: MEA Market Attractiveness by Drug, 2023 to 2033 Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
